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Abstract 
Cancer–related fatigue (CRF)  in a palliative care setting is a distressing symptom which can 
have a negative impact on  a patient’s quality of life. A range of setting and disease specific factors, 
unknown etiology and absence of unilateral guidelines makes CRF treatment a challenge for 
clinicians. In the absence of high-quality evidence in favour of any pharmacological and non-
pharmacological measures, except exercise, cognitive behavioural therapy and psychosocial 
interventions, a personalized integrative oncology approach can lead to effective management. 
Findings suggest a severity-based symptom-stage adjusted CRF management care pathway, 
highlighting best practices to illustrate the lived experience of this symptom. Overcoming barriers by 
staff training, patient education, facilitating communication and patients’ self-care, will increase CRF 
management effectiveness. Future CRF multi-symptomed or multidimensional nature investigation 
trials of its underlying mechanisms and new pharmacological and non-pharmacological strategies 
applied separately or in combination, will allow revealing the best approach to CRF diagnosis, 
assessment and management.  
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Introduction 
Cancer-related fatigue (CRF) experienced by patients in a palliative care setting is a severe 
symptom, with complexity of its assessment and management being stipulated by a range of setting- 
and disease-specific factors including lack of precise guidelines and insufficient evidence. A careful 
analysis of existing CRF assessment models, with application of integrative oncology methods, can 
ensure both ethical and professional approaches and effective palliation. This article proposes 
solutions for an optimal CRF care pathway in palliative setting and reveals the areas for future 
research to optimize current CRF treatment strategies. 
Prevalence 
The discrepancies in the reported prevalence rates of cancer-related fatigue (CRF) range from 
33 to 99% (Peters et al., 2014). Although many patients are either too weak for participation in 
studies (O’Regan, 2008), or deem CRF “untreatable” (Borneman, 2013), all of them rank it as one of 
the most distressing symptoms, severely affecting their quality of life (QOL) (Peters et al., 2014). 
Definition  
There is no commonly agreed definition of fatigue and CRF in particular (Donovan et al., 
2012). It fits neither in the available chronic fatigue nor in psychogenic fatigue syndrome (ICD-10, 
2010) definitions as a separate disease with its own etiology and pathogenesis (Raaf et al., 2013). 
The core features of CRF derived from different definitions are its subjectivity, the degree of 
impairment it implies and its abnormally high level and negative QOL effect (ICD-10, 2010; NCCN 
2014). Subjectivity remains the main problem as no individuals experience CRF in the same way and 
clinicians should rely entirely on patients’ description (Borneman, 2013).  
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Assessment  
Apart from acknowledged physical and cognitive dimensions of fatigue, there is still a 
dilemma whether CRF is a multidimensional or multi-symptomed notion (Donovan et al., 2012). If 
physical and mental fatigues are different symptoms, each having their own pathogenesis, the 
clinician should assess and treat them differently (Raaf et al., 2013). The range of setting- and 
disease-specific factors contributes to the definition of CRF rather as a complex syndrome, than an 
isolated symptom. Lack of  recognition and knowledge to treat CRF makes assessment a challenge 
(Borneman, 2013). The patients should always be asked about fatigue and what the symptom means 
to them as they may fail to report this due to religious beliefs (deeming it essential for fighting 
spirit,) or to fear of affecting medical treatment if reported (Borneman, 2013).  
Setting-specific. At the advanced disease stage, CRF can arise from clusters of poorly 
managed symptoms (pain, dyspnoea, cachexia), effects of multiple drugs interaction (steroids, 
benzodiazepines, opioids) and their fatigue-enhancing side effects on central nervous system (Bower, 
2014). It’s worth analyzing all the co-morbidities as each of them can lead to a vicious circle where 
CRF enhances other symptoms and increases its severity. Still, the separate effect of these co-
morbidities in patients requiring palliative care can be difficult to assess (Raaf et al., 2013) as few 
comparative studies show the precipitating and perpetuating factors for fatigue are different at 
different cancer stages. Treatment duration and the time spells\overlaps between different treatment 
stages should be considered, as CRF increases in subsequent treatment lines, being one of long-
lasting (5-10 years) side effects of previous treatments (Bower, 2014). 
Disease-specific. Increased immune and pro-inflammatory response in patients with advanced 
cancer plays a core role in CRF pathogenesis (Bower, 2014). Τhe changes in the immune system are 
enhanced by immunosuppressive tumor microenvironment with increased release of pro-
inflammatory IL-family cytokines.  Serotonin disregulation, dopamine alterations in the brain, HPA 
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axis activation are other CRF-enhancing factors (Bower, 2014). CRF severity is closely associated 
with cancer-specific co-morbidities (anaemia, paraneoplastic processes, sepsis) increasing during the 
disease trajectory (Bower, 2014; Peters et al., 2014).  
Psychological factors such as fear of recurrence, cognitive dysfunction, disrupted sleep\activity 
patterns, anxiety and depression are of core importance (Bower, 2014).  
Multiple patho-psychological and patho-physiological mechanisms of disease (Mustian et al., 
2007) play a unique a role for each patient, with the etiology of the majority being unknown (Peters 
et al., 2014). The holistic approach thus becomes an integral part of patient assessment. The critical 
evaluation of each specific factor's weight should be made based on the patient’s medical history, 
socio-demographic characteristics, religious and spiritual beliefs, physical and mental status 
(O’Regan, 2008) (Table 1). NCCN (2014) recommends a multifaceted assessment to be held at the 
patient’s initial clinic visit and at regular intervals afterwards (evidence level 2A) (Table 2) 
depending on the patient’s health status.  
Fatigue assessment tools and models. There is a variety of fatigue assessment tools in clinical 
practice, but no tool of choice exists. The most popular multidimensional tools are Multidimensional 
Fatigue Inventory Multidimensional Fatigue Symptom Inventory, Fatigue Questionnaire, Fatigue 
Assessment Questionnaire, Cancer Fatigue Scale, and Revised Piper Fatigue Scale (Raaf et al., 
2013). Each of these questionnaires is proven useful to assess CRF by a number of studies (Raaf et 
al., 2013), but their use is associated with certain limitations. Τhey are hardly comparable both in the 
same CRF-measuring aspects (e.g. “mental” as concentration and “mental” as memory\slips of 
tongue) (Donovan et al., 2012; Raaf et al., 2013) and in the subscales for physical and mental fatigue 
dimensions (Raaf et al., 2013). Only a few studies describe use of these tools to assess fatigue in 
advanced cancer and there are no studies comparing the effectiveness of each tool (Donovan et al., 
2012). Both UK and other available fatigue assessment models and guidelines are either not disease-
specific (NHSS, 2013) or not setting-specific (CPAC, 2011), or contain only specific guidance 
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(NICE CG81, 2014). NCCN (2014) are the only guidelines where a chapter is dedicated to CRF in a 
palliative care setting. However some patients may have problems with the NCCN (2014) numerical 
scale, finding it difficult to assign numbers or needing lengthier expressions (Donovan et al., 2012). 
NHSS (2013) suggests alternative verbal staging (mild, moderate, and severe) but is not specifically 
designed for oncology. Therefore, there is a clear need for a tool adjusted for the patients with 
advanced cancer.  
Although NCCN (2014) is the only disease stage-based guideline, the CPAC (2011) approach 
with its three-staged pathway (screening, comprehensive and focused assessment) is recommended 
(Donovan et al 2012; Borneman 2013) as a basis of assessment. It gives the most comprehensive 
picture of patient’s conditions, symptoms and prognosis (Table 3), enhancing the particular 
importance of referral possibilities and appropriate clinical knowledge and professionalism of MDT 
assessors (CPAC, 2011). However CPAC (2011) needs more precision in the assessment criteria 
(e.g. “regular intervals”). Peters et al., (2004) stress that the effects of dynamic changes over the 
disease trajectory also need to be integrated within the model. 
Management 
 Two CRF care pathways approaches are proposed by CPAC\NCCN guidelines: severity-
based (CPAC, 2011) or disease stage-based (NCCN, 2014) (Table 4); in practice, the combination of 
both is often required to individually tailor interventions (Peters et al., 2014). CRF management is a 
difficult task and though a causal (etiological) approach is advocated by some authors (Barnes and 
Bruera, 2002), all guidelines are based on holistic symptomatic management (CPAC 2011; NHSS 
2013; NCCN 2014; NICE CG81 2014). Another approach is targeting specific symptoms. However, 
the setting where whole clusters rather than isolated symptoms are present (Roxburgh
 
and McMillan, 
2014), suggests addressing the whole chain of co-morbidities, though their interaction may not 
always be known (O’Regan, 2008). So the concept “treat the symptoms not the syndrome” (cluster-
based) is proposed by the authors (Table 5). 
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General measures (GM). Energy conservation measures, daily scheduling, distraction and 
relaxation techniques with constant self-monitoring of fatigue levels, are the core of both CPAC and 
NCCN recommendations (evidence level 2A (CPAC, 2011; NCCN 2014) (Table 2). Patient 
education about patterns, causes, consequences and ways of CRF management aimed at  self-control, 
are key general strategies aimed at overcoming  patient barriers and identifying treatment targets 
(Mustian et al., 2007). 
Pharmacological measures (PM). Several groups of medications have been used to treat 
CRF but high quality evidence in favour of any is insufficient (CPAC 2011; NCCN 2014). The 
Cochrane review of 50 studies of CRF pharmacological management showed contradictory results 
for psychostimulants, both methylphenidate (27 trials) and modafinil (4 open-label studies), due to 
its frequent adverse effects (anorexia, insomnia, nausea, tachycardia),  with a recommendation for a 
large scale RCT to enable their approval for use in CRF (Minton et al., 2010). These findings are 
corroborated by the results of the recent large Cochrane review (45 studies, 4696 participants with 
advanced stage diseases, with cancer being primary diagnosis in majority of them (n =3223)) which 
demonstrated only some low quality evidence in favour of methylphenidate improving CRF (Mücke 
et al., 2015). Both CPAC (2011) and NCCN (2014) restrict the use of psycho-stimulants to  when 
other measures failed (evidence level 2A) (Table 2). Interestingly, antidepressants- paroxetine and 
sertraline, did not demonstrate such positive effect as psycho-stimulants, though improved mood 
and depression in CRF patients was noted (Minton et al., 2010). Consequently CPAC (2011) 
included them only for selected patients, and NCCN (2014) approved them under a “sleep 
medication” label to address insomnia\anxiety. The same review recommended against the use of 
haematopoietic growth factors darbepoetin and erythropoietin, due to frequent adverse effects, in 
spite of significant reduction in the level of anemia-induced CRF (Minton et al., 2010). For safety 
reasons and high costs, they were finally recommended only for selected patients after careful risk-
benefit analysis by NCCN 2014 (evidence level 2A) (Table 2) and recommended against by CPAC 
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(2011). Progestational steroids demonstrated no difference with placebo in 4 studies (Minton et al., 
2010); which however was contradictory to the previous RCTs’ results of significant appetite\QOL 
improvement (Caroll et al., 2007). NCCN (2014) allowed progestagens (megestrol acetate) for 
patients with CRF due to anorexia\cachexia for optimization of nutritional deficit, but no evidence 
level was assigned to this recommendation. CPAC (2011) found no evidence to recommend  the use 
of progestagens. The evidence-base for all corticosteroids was generally scarce, with short-term 
studies without exact dosage (Caroll et al 2007; Lai and Shung 2011). However, their ability to 
improve QOL in CRF was recognized.  NCCN (2014) approved dexamethasone\prednisolone only, 
while CPAC (2011) approved all of them generally (evidence level 2A) (Table 2).  
 New treatments of CRF suggested either lack evidence from RCT (NSAID, amantadine; L-
carnitine), or were not tested in palliative care (ginseng) and did not prove effective in cancer 
(cholinesterase inhibitors - donepezil) populations (Minton et al., 2010; Mücke et al., 2015). That 
explains wide discrepancies in different guidelines (Table 4), with a general rule to apply 
pharmacology as a last resort (evidence level 2A) (Table 2), carefully weighing risks and benefits 
(CPAC 2011; NCCN 2014).  Future clinical trials are necessary to justify use of different drugs 
classes (Mücke et al., 2015). 
Non-pharmacological measures (NPM).The choice and optimal combination of NPM for 
CRF management in a palliative care setting is disputable due to limited and heterogeneous evidence 
(Sood, 2007; Borneman, 2013). Activity enhancement (exercise), psychosocial therapy such as 
cognitive behavioral therapy (CBT) and physical interventions (massage, yoga) can be helpful in a 
majority of cases where no specific CRF causes can be defined, or where other means are not 
effective (NCCN, 2014). The integrative oncology approach  to CRF is based on the combination of 
conventional and complementary medicine, but harms and benefits of all complementary 
interventions should be determined (Bar-Sela et al., 2007) both on a  general  and individual level, 
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accounting for performance, mental and physical status, and disease trajectory of each patient (Sood, 
2007).  
Exercise (walking, cycling, swimming, aerobics), CBT and psychosocial interventions have 
the firmest evidence base (evidence level 1) (Table 2) for CRF (CPAC, 2011; NCCN, 2014) and are 
included in all guidelines. Available RCTs suggest exercise is well tolerated and effective in 
improving fitness, strength, functional capacity and emotional well-being of patients (Quist et al., 
2013). Both home and supervised exercise demonstrated this, although indicating a need for tailor-
made programmes, as general ones weighted effect is relatively small (ES = 0.16, 95% CI, –0.23 to 
0.54 post-treatment ) (Schmitz et al., 2005). Matching the exercise level to the individual patient’s 
characteristics will require new phase III trials (Quist et al., 2013).  
A specific model of CRF-perpetuating psychosocial factors tested in cancer survivors proved 
to be successful in advanced stage cancer in RCT (Peters et al., 2014) indicating cognitive behavioral 
therapy effectiveness individually and in groups, in both oral and written form and even if provided 
by a trained nonprofessional (Mustian et al., 2007).  
Sleep therapy and nutrition consultations are supported by expert opinion (Lai and Shung, 
2011) and graded evidence level 2A (NCCN 2014) (Table 2). The studies of massage, acupuncture, 
art, polarity therapy and yoga in cancer were sporadic, even for those demonstrating benefits (Bar -
Sela et al., 2007) and neither their single effectiveness nor their most effective combination with 
other NPM was revealed (Mustian et al., 2007). As physical interventions have the weakest evidence 
(Sood, 2007) they are not covered by most guidelines, except massage\acupuncture in CPAC (2011). 
Future RCT should define optimal NPM dose\delivery methods, safety throughout disease 
progression, and their most effective combinations (Mustian et al., 2007). The integrated care 
pathway proposed in Table 6 based on CPAC (2011) approach combines integrative oncology 
strategies and general techniques, depending on CRF severity and disease stage.  
Ethical, cultural issues and professional boundaries.  
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The principle of beneficence requires discussions with patients and their carer to find the best 
CRF management strategies. However, this principle may also need to be pursued in cases where 
fragile patients, unable to express what the symptom means to them or cannot provide information, 
by ascertaining this information from relatives or those close to the patient (Lai and Shung, 2011). 
Respecting a patient’s autonomy (Beauchamp and Childress, 2013) in what the symptom means to 
them and how they feel needs to be satisfactorily is paramount in management. Patients also need to 
be supported as they work towards finding meaning in a symptom so inherently disabling 
(Krishnasamy, 1997). As CRF substantially affects the lives of patients’ caregivers, their needs have 
to be regularly assessed and reviewed, with continuous support and education for them to be able to 
recognize health changes, to administer medicines at home (non-maleficence) and to choose either 
home care or consider alternatives for the patient (justice) (Connoly and Milligan, 2014). Cultural 
sensitivity is required to overcome patient barriers, e.g. the use of interpreters to outline “fatigue” for 
non-English speaking patients, respect of spiritual concepts of people of different faiths (easier 
acceptance of fatigue by those who place more strength on their beliefs) (Borneman, 2013) and 
understanding of social contexts (e.g. beliefs how they should manage suffering according to gender 
roles). Professional issues include the need for effective communication with the patient in 
boundaries of professional, not “social” presence, where a sign of particular attention to one patient 
(e.g. personal mobile calls) can be perceived as a permission to require it for all others (Connoly and 
Milligan, 2014). Such a boundary breach can be prevented by, for example, providing a 7-day a 
week hot-line support for patients with CRF. The general long-standing rule should be empathic 
understanding, effective communication with expression of general interest, without impeding 
professional decision-making (O’Regan, 2008). 
Implications for Practice 
As most countries do not have specific guidelines for CRF management in palliative care, 
targeting multiple barriers in CRF management should result in a clear pathway possibly similar to 
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other chronic fatigue guidelines (e.g. NICE CG53, 2007; NICE CG 186, 2014), but taking into 
consideration cancer-specific differences (Roxburgh and McMillan, 2014). The integrated care 
pathway proposed by the authors (Table 6) is based on the CPAC (2011) three-stage assessment with 
concurrent disease staging (NCCN, 2014) and treatment adjustment to patient’s individual 
characteristics. Constant follow-up, with added frequency towards the end of life is applied to all 
interventions which are rescheduled as necessary in the course of the disease trajectory (Table 6). In 
the absence of generally aligned guidelines, the authors consider the proposed integrated care 
pathway a practical tool for everyday clinical practice, enhancing the MDT ability to apply effective 
strategies of CRF management and tailoring the approach to patients’ needs. Continuous staff 
training and patient and carer education to recognize the symptoms and to facilitate self-care should 
be provided (Connoly and Milligan, 2014).  
Research opportunities 
Apart from clinical practice, to increase effectiveness of CRF management, new trials in the 
palliative care setting are recommended. They should preferably be designed as RCT\ longitudinal 
studies (Donovan et al., 2012; Peters et al., 2014), rigorously comply with research methodology 
(Mustian et al., 2007) and choose different fatigue dimensions as outcome variables to understand 
each intervention effectiveness (Raaf et al., 2013). They have also to focus on integrative oncology 
approaches identifying optimal mode, frequency, intensity, duration, delivery methods, risks and 
benefits of PM and NPM, both separately and in the best available combinations (Bar-Sela et al., 
2007; Mustian et al 2007).  
Conclusion  
CRF in a palliative care setting is a widespread and a QOL-affecting symptom. It is a 
complex syndrome due a range of disease and setting related factors. An MDT approach can be 
enhanced by whole CRF multidimensional paradigm revision, defining a pathway to assess and treat 
different CRF domains. CRF assessment should be severity-based with use of optimal assessment 
11 
 
tools and simultaneous grading of the disease stage, resulting in identification of treatable symptoms 
and tailoring approach to the patients’ needs. The proposed model of CRF care pathway is based on 
the principle “treat the symptoms not the syndrome”. The integrative oncology approach supposes a 
combination of pharmacological and non-pharmacological strategies (exercise, psychosocial 
(evidence level 1) and physical techniques (evidence level 2A) (Table 2). The MDT should 
demonstrate ethical and cultural sensitivity acting within professional boundaries. In the absence of 
consensus on CRF management, general rules are usage of pharmacological strategies only in 
selected cases after careful risk-benefit analysis (evidence level 2A) (Table 2). Effects of 
cholinesterase inhibitors, NSAIDs, amantadine, L-carnitine are being investigated. There is a need 
for new complex models targeting the patient and staff barriers in CRF management as well as for 
new studies in search for effective treatment agents, best pharmacological and non-pharmacological 
strategies and combinations to refine current treatment approaches and to align existing guidelines. 
Finally, as was indicated several years ago by Krishnasamy (1997), as the patient approaches the end 
of life, there is a need to shift the focus of patients and all concerned with them, from the 
management of fatigue to facilitating the process of living with the fatigue of dying. 
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Tables 
Table 1. Factors making CRF a complex syndrome 
Barriers to target 
Setting-specific 
Multiple factors overlap in palliative setting 
Precipitating and perpetuating factors different from other disease stages 
Lack of research for palliative population 
Absence of guidelines for palliative population 
Disease-specific 
Cancer-induced changes in immune and other systems  
Cancer-specific symptoms\comorbidities  increasing during disease trajectory 
Cancer-related psychological factors 
Source: Mustian et al (2007); Bower (2014); Raaf et al (2013); Peters et al (2014) 
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Table 2. Levels of Evidence  
1A Systematic review (with homogeneity) of RCTs 
1B Individual RCT (with narrow confidence intervals) 
1C All or none study 
2A Systematic review (with homogeneity) of cohort studies 
2B Individual Cohort study (including low quality RCT, e.g. <80% follow-up) 
2C “Outcomes” research; Ecological studies 
3A Systematic review (with homogeneity) of case-control studies 
3B Individual Case-control study 
4 Case series (and poor quality cohort and case-control study 
5 Expert opinion without explicit critical appraisal or based on physiology bench research or 
“first principles” 
Source: CEBM (2015) 
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Table 3. Comparative table of CRF assessment approaches in different national guidelines. 
 A Pan-Canadian 
Practice Guideline 
CPAC (2011) 
National 
Comprehensive 
Cancer Network 
(NCCN) (2014) 
National Health 
Service Scotland 
NHSS(2013) 
National Institute for 
Clinical Excellence 
NICE  CG81(2014)” 
 
Specificity      
Cancer specific Yes Yes No Yes (breast cancer 
only) 
Palliative setting 
specific 
No Only in 
interventions choice  
Yes Yes 
Screening     
Interview  Yes Yes Yes Yes 
Assessment Tools 
Usage 
PFS\ ESAS* Simple numeric 
rating 
Severity rating or 
numeric 
No recommendation 
Comprehensive 
assessment 
    
Focused history and 
physical exam 
Yes Yes Partly No recommendation 
Contributing factors, 
diagnosis (current 
status)and treatment 
details, 
comorbidities  
Yes Yes Yes Yes 
Psychosocial factors  Yes Only sleep patterns Not separated  as 
alleviating 
No recommendation 
Alcohol drugs abuse Yes Yes No No recommendation 
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Activity level 
current and 
functional status 
Yes Yes No No 
Focused assessment     
Treatable factors 
identification  
 
Yes 
 
 
Yes 
 
Yes Yes 
Need for referral 
identification 
No No 
“only parts 1.5.8-1.5.10 dedicated to CRF 
*PFS –Piper Fatigue Scale; ESAS –Edmonton Symptom Assessment System 
Source: CPAC (2011); NHSS (2013); NCCN (2014); NICE (2014) 
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Table 4. Comparative table of recommended CRF interventions in different national guidelines  
(with evidence level where available) 
 A Pan-Canadian 
Practice Guideline 
CPAC (2011) 
National 
Comprehensive 
Cancer Network 
(NCCN) (2014) 
National Health 
Service Scotland 
NHSS(2013) 
National Institute for 
Clinical Excellence 
NICE  CG81 (2014) 
 
General     
Energy conservation 
measures\self-monitoring 
 
 
2A 
 
 
 
2A 
 
 
 
Yes 
No 
Patients\carers education 
and counselling 
Yes 
Pharmacological     
Psychostimulants Not recommended 
except in selected 
patients in EOL 
(2A) 
2A*, 
 
No  
 
N\a** 
 
Corticosteroids  
N\a ** 
 
Antidepressants 2A *, 
Haematopoietic growth 
factors 
No 2A 
Progestagens  No Yes*** Yes 
Non-pharmacological      
Exercise  
 
 
 
 
2A 
 
1 
 
 
Yes 
 
 
Yes Psychosocial 
interventions\cognitive 
behavioural therapy 
Sleep and nutrition 
counselling 
2A Yes  
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Stress reduction 
strategies: massage, 
yoga, muscle relaxation, 
relaxation guided 
imagery, acupuncture 
 No  
 
N\a** 
 
 
 
N\a** 
 
Attention-restoring 
therapy 
2A 
“only parts 1.5.8-1.5.10 dedicated to CRF 
after ruling out all other possible causes 
* under “sleep medication” label 
** not mentioned at all  
*** for optimization of  nutritional deficit\imbalance treatment 
Source: CPAC (2011); NHSS (2013); NCCN (2014); NICE (2014) 
  
18 
 
Table 5. Symptoms-based CRF management approach 
Symptoms cluster accompanying CRF Possible ways to 
manage 
C
A
N
C
E
R
-R
E
L
A
T
E
D
 F
A
T
IG
U
E
 
Depression Pain Distraction techniques 
Behavioural therapies 
Antidepressants 
Opioids 
Corticosteroids 
Anxiety Breathlessness\dyspnoea Cognitive behavioral 
therapy 
Distraction techniques 
Sedation 
Opioids 
Sleep disorders Insomnia Sleep therapy 
Antidepressants 
Anaemia Muscle loss Exercise 
Erythropoietins 
L-Carnitine* 
Anorexia\Cachexia Dehydration Nutrition counselling 
Progestagens 
Biphosphonates** 
Infection, sepsis, fever  Antibiotics 
Sleep therapy 
Pulmonary and cardiac disorders, renal and hepatic failure, paraneoplastic 
neurological syndromes 
Drugs per related 
guidelines 
Other integrative 
therapies 
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Endocrine abnormalities, hypothyroidism or hypogonadism Hormone replacement 
therapy 
Nutrition counselling 
* experimental treatment 
** for electrolytes imbalance 
Source: Barnes and Bruera (2002); O’Regan (2008); Lai and Shung (2011); Bower (2014) 
  
20 
 
Table 6. Integrated care pathway proposed for CRF management in a palliative care setting 
Steps Action plan 
Screening (CPAC 2011, 
NCCN 2014) 
Subjective (patient’s narrative) 
Objective symptoms (physical examinations, laboratory tests) 
History and current disease stage\treatment status 
Comorbidities\ medications 
Physical and psychosocial conditions 
Comprehensive assessment QOL impact (CPAC, 2011) 
The meaning of the fatigue to the patient (Krishnasamy, 1997) 
Etiology (Barnes and Bruera, 2002; CPAC, 2011) 
CRF severity and temporal features (CPAC, 2011; NCCN 2014) 
Exacerbating and relieving factors (CPAC, 2011; NCCN 2014) 
Precipitating and perpetuating factors (Raaf et al., 2013) 
Scoring (Edmonton Symptom Assessment System \Piper Scale\simple 
numbers\verbal staging)(CPAC 2011; Donovan et al.,2012; Borneman et al., 
2013; Raaf et al., 2013; NCCN, 2014) 
Focused assessment Identifying treatable factors (Mustian et al.,2007) 
Screening for the  setting-related factors ( past treatment long-lasting effects 
current treatment effects, drugs’ overlapping  side effects ( polypharmacy) 
comorbidities  inherent to diagnosis\disease stage) (O’Regan, 2008; CPAC. 
2011; Bower. 2014; NCCN. 2014) 
Assessing psychological status (depression?) (O’Regan, 2008; NCCN. 
2014) 
Need for referral (CPAC. 2011) 
Need for related guidelines use (comorbidities) (NCCN. 2011; Bower. 2014; 
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NCCN. 2014; Peters et al., 2014) 
Choice  and implementation 
of care model (CPAC 2011, 
NCCN 2014) 
Mild – education and counselling 
Exclude effect of past treatments 
If not successful  -treatment as moderate, after review 
Moderate - education, counselling (energy and sleep, restoration, family 
interactions, nutritional therapy, general information and support groups) and 
NPM.  
Contributing factors\comorbidities treatment 
If not successful - treatment as severe, after review 
Severe - urgent management of  contributing factors\comorbidities – PM, 
addressing safety issues ( falls,  syncope) 
Excluding  cancer further progression 
Evaluation and monitoring Effectiveness evaluation(CPAC,2011; NCCN, 2014) 
Constant review and reassessment throughout disease trajectory (Donovan et 
al., 2012, Peters et al., 2014) 
Regular monitoring, with more frequent intervals up to the end of life 
(CPAC,2011; NCCN, 2014) 
Source: Krishnasamy (1997); Barnes and Bruera (2002); Mustian et al (2007); O’Regan (2008); CPAC 
(2011); Donovan et al (2012); Raaf et al (2013); Bower (2014); Peters et al (2014); NCCN (2014) 
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